221 related articles for article (PubMed ID: 27434392)
21. Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Rosenson RS; Tangney CC; Schaefer EJ
Atherosclerosis; 2001 Apr; 155(2):463-6. PubMed ID: 11254918
[TBL] [Abstract][Full Text] [Related]
22. Variable influence of statins on isoprostanes in hyperlipidemia.
Sinzinger H; Oguogho A
Adv Exp Med Biol; 2003; 525():209-12. PubMed ID: 12751770
[No Abstract] [Full Text] [Related]
23. A Population-Based Cohort Study on the Drug-Specific Effect of Statins on Sepsis Outcome.
Lee CC; Lee MG; Hsu TC; Porta L; Chang SS; Yo CH; Tsai KC; Lee M
Chest; 2018 Apr; 153(4):805-815. PubMed ID: 28962887
[TBL] [Abstract][Full Text] [Related]
24. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
[TBL] [Abstract][Full Text] [Related]
25. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Novaro GM; Tiong IY; Pearce GL; Lauer MS; Sprecher DL; Griffin BP
Circulation; 2001 Oct; 104(18):2205-9. PubMed ID: 11684632
[TBL] [Abstract][Full Text] [Related]
26. Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Davidson M
Prev Cardiol; 2005; 8(4):244-9. PubMed ID: 16230879
[TBL] [Abstract][Full Text] [Related]
27. Risk of incident diabetes among patients treated with statins: population based study.
Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Neuvonen PJ; Backman JT; Niemi M
Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
[TBL] [Abstract][Full Text] [Related]
29. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
Bener A; Dogan M; Barakat L; Al-Hamaq AO
J Prim Care Community Health; 2014 Jul; 5(3):180-7. PubMed ID: 24522932
[TBL] [Abstract][Full Text] [Related]
31. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
[TBL] [Abstract][Full Text] [Related]
32. Quantifying the use of the statin antilipemic drugs: comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia.
Cooke C; Nissen L; Sketris I; Tett SE
Clin Ther; 2005 Apr; 27(4):497-508. PubMed ID: 15922822
[TBL] [Abstract][Full Text] [Related]
33. The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target.
Lum CJ; Nakagawa K; Shohet RV; Seto TB; Taira DA
Hawaii J Med Public Health; 2017 Apr; 76(4):99-102. PubMed ID: 28428922
[TBL] [Abstract][Full Text] [Related]
34. Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Kato T; Tokoro T; Namii Y; Kobayashi T; Hayashi S; Yokoyama I; Morimoto S; Chan M; Giannetti N; Hunt SA
Transplant Proc; 2000 Mar; 32(2):331-3. PubMed ID: 10715431
[No Abstract] [Full Text] [Related]
35. Statin wars following coronary revascularization--evidence-based clinical practice?
Brophy JM; Costa V
Can J Cardiol; 2006 Jan; 22(1):54-8. PubMed ID: 16450018
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
Milner E; Ainsworth M; Gleaton M; Bookstaver D
J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137
[TBL] [Abstract][Full Text] [Related]
38. Antipsychotic Drug Dispensations in Older Adults, Including Continuation After a Fall-Related Hospitalization: Identifying Adherence to Screening Tool of Older Persons' Potentially Inappropriate Prescriptions Criteria Using the Nova Scotia Seniors' Pharmacare Program and Canadian Institute for Health's Discharge Databases.
Trenaman SC; Hill-Taylor BJ; Matheson KJ; Gardner DM; Sketris IS
Curr Ther Res Clin Exp; 2018; 89():27-36. PubMed ID: 30294400
[TBL] [Abstract][Full Text] [Related]
39. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study.
Settergren J; Eiermann B; Mannheimer B
PLoS One; 2013; 8(8):e69545. PubMed ID: 23940522
[TBL] [Abstract][Full Text] [Related]
40. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
